Veltassa 8.4 g powder for oral suspension

DRUG3 trials

Sponsors

Fundacion Para La Investigacion Biomedica De Cordoba, Mario Negri Institute For Pharmacological Research IRCCS, Istituto Di Ricerche Farmacologiche Mario Negri

Conditions

Chronic kindney diseaseEnd Stage Kidney Disease on chronic dialysis therapyHyyperkalemia in CKD stage IIIB to V patients

Phase 2

Double-blind, placebo-controlled clinical trial to determine the effect of Patiromer on vascular function and its relationship with mineral metabolism parameters

CompletedCTIS2023-503941-69-00

Fundacion Para La Investigacion Biomedica De CordobaChronic kindney disease

Start: 2024-07-04End: 2025-09-03Target: 40Updated: 2023-07-24

Phase 3

A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dialysis patients with CKD stage IIIB to Vrandomized to Patiromer or placebo

CompletedCTIS2023-503984-41-00

Mario Negri Institute For Pharmacological Research IRCCSHyyperkalemia in CKD stage IIIB to V patients

Start: 2023-08-02End: 2024-10-16Target: 1Updated: 2023-10-17

Impact of Patiromer treatment on dietary Potassium intake restriction and health-related quality of life and nutrition in patients on Chronic Dialysis Therapy: a Double-Blind, Prospective, Randomized, Placebo-Controlled, Pilot Trial

RecruitingCTIS2025-521378-33-00

Istituto Di Ricerche Farmacologiche Mario NegriEnd Stage Kidney Disease on chronic dialysis therapy

Start: 2025-07-31Target: 40Updated: 2025-07-08